The role of AIM2 in T cell-mediated autoimmunity
AIM2 在 T 细胞介导的自身免疫中的作用
基本信息
- 批准号:10083178
- 负责人:
- 金额:$ 38.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-01-05 至 2022-12-31
- 项目状态:已结题
- 来源:
- 关键词:AIM2 geneAKT Signaling PathwayAffectAntigen-Presenting CellsAntigensAutoimmune DiseasesAutoimmune ProcessAutoimmunityAutomobile DrivingBindingCD4 Positive T LymphocytesCell CompartmentationCell DeathCell physiologyCellsCellular immunotherapyComplexDNADNA-dependent protein kinaseDefectDendritic CellsDevelopmentDiabetes MellitusEragrostisEventExhibitsFoundationsGoalsHomeostasisHost DefenseHumanHypersensitivityImmuneImmunotherapyInbred NOD MiceInflammasomeInflammationInsulin-Dependent Diabetes MellitusInterleukin-18Malignant NeoplasmsMediatingMediator of activation proteinMindModelingNatural ImmunityPI3K/AKTPathogenicityPathway interactionsPeripheralPhenotypePhosphorylationProductionPropertyProto-Oncogene Proteins c-aktRegulationRoleSelf ToleranceSignal PathwaySignal TransductionStimulusT-LymphocyteT-Lymphocyte SubsetsTestingTherapeuticThymic epithelial cellThymus GlandTissuesWorkbasecentral tolerancediabetogenicds-DNAimmunoregulationinsightnegative affectnovelpathogenpathogenic microbeperipheral tolerancepreventresponsesensor
项目摘要
SUMMARY/ABSTRACT
T cell-mediated autoimmune diseases such as Type 1 diabetes (T1D) are due to complex events leading to
dysregulation of central and peripheral tolerance. Defining the mechanisms regulating self-tolerance are critical
for understanding the autoimmune process as well as for rational development of immunotherapies to prevent
and treat T1D and other T cell-mediated autoimmune diseases.
This application is based on our novel observation that NOD mice deficient in the AIM2 inflammasome
molecule remain diabetes-free. AIM2 is a cytoplasmic immune sensor involved in host defense. Upon binding
double stranded DNA from a microbial pathogen, AIM2 assembles into an inflammasome complex that drives
the production of proinflammatory IL-1bβ and IL-18, and pyroptosis-mediated cell death. Recent studies,
however, have demonstrated that AIM2 can serve a regulatory function outside of host defense via a
nonconical pathway that is independent of inflammasome activation. Here, AIM2 functions as a negative
regulator of the kinase DNA-PK in the PI3K/AKT signaling pathway.
We find that the lack of diabetes in AIM2-deficient NOD mice is also independent of inflammasome activation.
Furthermore, evidence suggests that bβ cell autoimmunity in AIM2-deficient NOD mice is blocked by multiple
mechanisms affecting thymic antigen presenting cells, peripheral dendritic cell function and T cell subset
differentiation. We hypothesize that AIM2 serves as a key checkpoint in regulating PI3K/DNA-PK/AKT-
dependent stimuli and cellular maturation/differentiation, which impacts self-tolerance and the diabetogenic
response. Our goal is to define the key mechanisms by which AIM2 regulates self-tolerance. With this in mind,
Specific Aim 1 will focus on AIM2 effects on the stimulatory function of medullary thymic epithelial cells and
thymic dendritic cells. Specific Aim 2 will define the role of AIM2 in regulating dendritic cell proinflammatory
versus tolerogenic function. Finally, Specific Aim 3 will investigate how AIM2 controls the efficiency of
pathogenic T cell subset differentiation. This work is expected to provide insight into new mechanisms and
pathways by which central and peripheral self-tolerance are regulated, as well as a foundation to target the
AIM2 pathway for therapeutic purposes.
摘要/摘要
T细胞介导的自身免疫性疾病,如1型糖尿病(T1D),是由于复杂的事件导致的
中枢和外周耐受性失调。确定调节自我容忍的机制至关重要
了解自身免疫过程以及合理开发免疫疗法以预防
治疗T1D和其他T细胞介导的自身免疫性疾病。
这一应用是基于我们新的观察结果,即NOD小鼠缺乏AIM2炎症小体
分子仍未患上糖尿病。AIM2是一种参与宿主防御的细胞质免疫感受器。在绑定时
来自微生物病原体的双链DNA,AIM2组装成一个炎症体复合体,驱动
促炎因子IL-1bβ和IL-18的产生,以及由下垂引起的细胞死亡。最近的研究表明,
然而,AIM2已经证明了AIM2可以通过一个
不依赖于炎性小体激活的非锥形通路。在这里,AIM2起否定的作用
PI3K/AKT信号通路中的激酶DNA--PK调节因子。
我们发现,AIM2缺陷的NOD小鼠中糖尿病的缺乏也独立于炎症体的激活。
此外,有证据表明,在aim2基因缺陷的NOD小鼠中,bβ细胞的自身免疫被多个
胸腺抗原提呈细胞、外周血树突状细胞功能及T细胞亚群的影响机制
差异化。我们假设AIM2是调控PI3K/DNA-PK/AKT-的关键检查点。
依赖刺激和细胞成熟/分化影响自身耐受性和糖尿病的发生
回应。我们的目标是定义AIM2调节自我耐受的关键机制。考虑到这一点,
具体目标1将集中在AIM2对延髓胸腺上皮细胞刺激功能的影响和
胸腺树突状细胞。特异性目标2将确定AIM2在调节树突状细胞致炎中的作用
而不是耐受性功能。最后,《特定目标3》将调查AIM2如何控制
致病T细胞亚群分化。这项工作有望为深入了解新的机制和
调节中枢和外周自我耐受的途径,以及靶向
用于治疗目的的AIM2途径。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Roland M Tisch其他文献
Roland M Tisch的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Roland M Tisch', 18)}}的其他基金
Enhancing antigen-based therapy for T1D by T cell coreceptor tuning
通过 T 细胞辅助受体调节增强基于抗原的 T1D 治疗
- 批准号:
10593245 - 财政年份:2022
- 资助金额:
$ 38.88万 - 项目类别:
ICES-based Pulsed Field Electromagnetic Field Therapy for Autoimmunity
基于 ICES 的自身免疫脉冲场电磁场治疗
- 批准号:
9903662 - 财政年份:2020
- 资助金额:
$ 38.88万 - 项目类别:
ICES-based Pulsed Field Electromagnetic Field Therapy for Autoimmunity
基于 ICES 的自身免疫脉冲场电磁场治疗
- 批准号:
10079462 - 财政年份:2020
- 资助金额:
$ 38.88万 - 项目类别:
Thymic and peripheral regulation of autoreactive T cells by coreceptor therapy
共受体治疗对胸腺和外周自身反应性 T 细胞的调节
- 批准号:
10395438 - 财政年份:2019
- 资助金额:
$ 38.88万 - 项目类别:
Thymic and peripheral regulation of autoreactive T cells by coreceptor therapy
共受体治疗对胸腺和外周自身反应性 T 细胞的调节
- 批准号:
10623181 - 财政年份:2019
- 资助金额:
$ 38.88万 - 项目类别:
The role of AIM2 in T cell-mediated autoimmunity
AIM2 在 T 细胞介导的自身免疫中的作用
- 批准号:
10321613 - 财政年份:2019
- 资助金额:
$ 38.88万 - 项目类别:
Combinatorial beta Cell-Specific Cytokine Therapy to Reverse Type I Diabetes
逆转 I 型糖尿病的组合 β 细胞特异性细胞因子疗法
- 批准号:
8911506 - 财政年份:2015
- 资助金额:
$ 38.88万 - 项目类别:
Combinatorial Beta Cell-Specific Cytokine Therapy to Reverse Type I Diabetes
逆转 I 型糖尿病的β细胞特异性细胞因子组合疗法
- 批准号:
9240623 - 财政年份:2015
- 资助金额:
$ 38.88万 - 项目类别:
Islet-Specific Tolerance Induced by T Cell Co-Receptor Therapy in Type 1 Diabetes
T 细胞辅助受体治疗在 1 型糖尿病中诱导的胰岛特异性耐受
- 批准号:
8725412 - 财政年份:2014
- 资助金额:
$ 38.88万 - 项目类别:
Islet-Specific Tolerance Induced by T Cell Co-Receptor Therapy in Type 1 Diabetes
T 细胞辅助受体治疗在 1 型糖尿病中诱导的胰岛特异性耐受
- 批准号:
8829828 - 财政年份:2014
- 资助金额:
$ 38.88万 - 项目类别:
相似海外基金
Myocardial preconditioning effects of amino acids and PI3K/Akt signaling pathway
氨基酸和PI3K/Akt信号通路的心肌预适应作用
- 批准号:
16K10955 - 财政年份:2016
- 资助金额:
$ 38.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Myocardial preconditioning effects of high-dose insulin and PI3K/Akt signaling pathway
大剂量胰岛素及PI3K/Akt信号通路对心肌的预处理作用
- 批准号:
25462429 - 财政年份:2013
- 资助金额:
$ 38.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Functional analysis of the PI3K/Akt signaling pathway during the mammalian inner ear development and its application for regenerative medicine
哺乳动物内耳发育过程中PI3K/Akt信号通路的功能分析及其在再生医学中的应用
- 批准号:
23592496 - 财政年份:2011
- 资助金额:
$ 38.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Analysis of regulatory mechanism of PI3K-Akt signaling pathway by TTC3
TTC3对PI3K-Akt信号通路的调控机制分析
- 批准号:
22770118 - 财政年份:2010
- 资助金额:
$ 38.88万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Gq-coupled Receptors Inhibit PI 3-kinase/Akt Signaling Pathway
Gq 偶联受体抑制 PI 3 激酶/Akt 信号通路
- 批准号:
8003647 - 财政年份:2009
- 资助金额:
$ 38.88万 - 项目类别:
Molecular Therapy Targeting PTEN-Akt Signaling Pathway in Prostate Cancer.
前列腺癌中针对 PTEN-Akt 信号通路的分子治疗。
- 批准号:
17591697 - 财政年份:2005
- 资助金额:
$ 38.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Gq-coupled Receptors Inhibit PI 3-kinase/Akt Signaling Pathway
Gq 偶联受体抑制 PI 3 激酶/Akt 信号通路
- 批准号:
7525551 - 财政年份:2002
- 资助金额:
$ 38.88万 - 项目类别:
Gq-coupled Receptors Inhibit PI 3-kinase/Akt Signaling Pathway
Gq 偶联受体抑制 PI 3 激酶/Akt 信号通路
- 批准号:
7645586 - 财政年份:2002
- 资助金额:
$ 38.88万 - 项目类别:
Gq-Coupled Receptors Inhibit PI 3-Kinase/Akt Signaling Pathway
Gq 偶联受体抑制 PI 3 激酶/Akt 信号通路
- 批准号:
8064263 - 财政年份:2002
- 资助金额:
$ 38.88万 - 项目类别:
Gq-Coupled Receptors Inhibit PI 3-Kinase/Akt Signaling Pathway
Gq 偶联受体抑制 PI 3 激酶/Akt 信号通路
- 批准号:
8274809 - 财政年份:2002
- 资助金额:
$ 38.88万 - 项目类别:














{{item.name}}会员




